¡Ya estamos en ! Descubre más
icono de AMRX

Amneal Pharmaceuticals

19.18 USD
-0.07
0.36%
Al cierre Actualizado 16 oct, 4:00 p.m. EDT
Antes de la apertura del mercado
Después del cierre del mercado
19.75
+0.57
2.97%
1 día
-0.36%
5 días
-4.29%
1 mes
6.08%
3 meses
6.32%
6 meses
46.52%
En lo que va del año
51.5%
1 año
94.33%
5 años
243.73%
10 años
27.78%
 

Acerca de: Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Empleados: 8,500

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 40.9%
Neutral 54.5%
Negativo 4.5%
Neutral
GlobeNewsWire
hace 8 días
Amneal to Report Third Quarter 2026 Results on November 3, 2026
BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.
Amneal to Report Third Quarter 2026 Results on November 3, 2026
Neutral
GlobeNewsWire
hace 28 días
Amneal Announces FDA Approval and Launch of Lanreotide Injection
- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
Amneal Announces FDA Approval and Launch of Lanreotide Injection
Positivo
Zacks Investment Research
hace 29 días
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
Neutral
Zacks Investment Research
el mes pasado
5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low
COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.
5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low
Negativo
Zacks Investment Research
el mes pasado
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
Neutral
Business Wire
el mes pasado
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)---- $AMRX #AMRX--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company's current shareholders.The investigation seeks to determine whether Amneal or the company's officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional informat.
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm
Positivo
Zacks Investment Research
el mes pasado
5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns
Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.
5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns
Neutral
Zacks Investment Research
hace 2 meses
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
Neutral
Zacks Investment Research
hace 2 meses
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
Positivo
Zacks Investment Research
hace 2 meses
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?
Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?
Gráficos de precios implementados con Lightweight Charts™